Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan
-
- Ayano Okabe
- Department of Regulatory Science, Faculty of Pharmacy, Meiji Pharmaceutical University, Tokyo 204-8588, Japan
-
- Haruto Hayashi
- Department of Regulatory Science, Faculty of Pharmacy, Meiji Pharmaceutical University, Tokyo 204-8588, Japan
-
- Hideki Maeda
- Department of Regulatory Science, Faculty of Pharmacy, Meiji Pharmaceutical University, Tokyo 204-8588, Japan
書誌事項
- 公開日
- 2023-02-01
- 資源種別
- journal article
- 権利情報
-
- https://creativecommons.org/licenses/by/4.0/
- DOI
-
- 10.3390/curroncol30020137
- 公開者
- MDPI AG
説明
<jats:p>Drug pricing methods vary extensively across countries. Japan calculates drug prices using cost accounting and based on the efficacy of similar drugs. This study investigated the relationship between drug prices and their clinical efficacy and usefulness using public information on anticancer drugs reimbursed by the National Health Insurance price listing between January 2009 and March 2020. We investigated drug characteristics, prices, and clinical benefits based on overall survival (OS) and progression-free survival (PFS). Eighty anticancer drugs were approved in Japan during the study period. The largest number (28 drugs, 35.0%) was approved based on PFS, 18 (22.5%) were approved based on OS, and 13 (16.3%) based on the response rate. The mean (±SD) drug price was JPY 88,416.2 (±148,974.7), while the median drug price (with quartiles) was JPY 21,694 (JPY 4855.0–JPY 93,396.8). Drug prices were significantly higher for PFS than for OS, while cost index—the drug price to extend PFS or OS by one day—did not differ significantly between PFS and OS. The relationship between the 46 drugs approved based on OS or PFS and their prices was examined. A correlation was found between drug prices and their clinical usefulness in terms of OS but not PFS.</jats:p>
収録刊行物
-
- Current Oncology
-
Current Oncology 30 (2), 1776-1783, 2023-02-01
MDPI AG